Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 9/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | SORD | Q00796 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30648204 | 1.00 | ALDH1A1 (0.41) | ALDH1A1SGMS2KDM4ENPC1TP53 | |
| Hydrochloric Acid SCHEMBL21581823 | 0.98 | SGMS2 (0.40) | ALDH1A1SGMS2KDM4ENPC1TP53 | |
| Hydrochloric Acid SCHEMBL29657324 | 0.98 | SGMS2 (0.40) | ALDH1A1SGMS2KDM4ENPC1TP53 | |
| SCHEMBL5140187 | 0.75 | ALDH1A1 (0.41) | ALDH1A1SGMS2KDM4ENPC1TP53 | |
| SCHEMBL30988533 | 0.75 | ELANE (0.44) | ALDH1A1SGMS2KDM4ENPC1TP53 | |
| SCHEMBL29657370 | 0.75 | ALDH1A1 (0.41) | ALDH1A1SGMS2KDM4ENPC1TP53 | |
| SCHEMBL2667239 | 0.75 | SGMS2 (0.46) | ALDH1A1SGMS2KDM4ENPC1TP53 | |
| SCHEMBL845891 | 0.75 | ALDH1A1 (0.41) | ALDH1A1SGMS2KDM4ENPC1TP53 | |
| SCHEMBL10278989 | 0.75 | ALDH1A1 (0.41) | ALDH1A1SGMS2KDM4ENPC1TP53 | |
| SCHEMBL30280440 | 0.75 | SGMS2 (0.46) | ALDH1A1SGMS2KDM4ENPC1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4634170-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | AstraZeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| US-20240409533-A1 | HMOX1 INDUCERS | Astellas Engineered Small Molecules US, Incorporated | 2024-12-12 | — | — | US | disclosed |
| US-12071433-B2 | HMOX1 inducers | Astellas Engineered Small Molecules US, Incorporated (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240239767-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-18 | — | — | US | disclosed |
| WO-2024126773-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-06-20 | — | — | WO | disclosed |
| US-20240174636-A1 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORPORATION (KR) | 2024-05-30 | — | — | US | disclosed |
| US-20240051952-A1 | HMOX1 INDUCERS | Astellas Engineered Small Molecules US, Incorporated | 2024-02-15 | — | — | US | disclosed |
| EP-4313965-A1 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Yuhan Corporation (KR) | 2024-02-07 | — | — | EP | disclosed |
| CN-117120423-A | Novel indoleamine 2,3-dioxygenase inhibitors, process for preparing the same and pharmaceutical compositions containing the same | 柳韩洋行 | 2023-11-24 | — | — | CN | disclosed |
| US-20190367499-A1 | Compounds for Pain Treatment, Compositions Comprising Same, and Methods of Using Same | ACADIA PHARMACEUTICALS INC. | 2019-12-05 | — | — | US | disclosed |
| WO-2019043407-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LIMITED (GB) | 2019-03-07 | — | — | WO | disclosed |
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| EP-2274288-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Incyte Corporation (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
| US-5616717-A | Process for the preparation of pure enantiomers of 1-(2-pyridyl)-2-cyclohexylethylamine | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1997-04-01 | — | — | US | disclosed |
| US-5552421-A | Leukotriene biosynthesis inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1996-09-03 | — | — | US | disclosed |
| US-5296486-A | Leukotriene biosynthesis inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 1994-03-22 | — | — | US | disclosed |
| EP-0535521-A2 | Condensed oxazole and thiazole derivatives as leukotriene biosynthesis inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1993-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | ALDH1A1 2511/4885SGMS2 2813/4885KDM4E 248/4885 |
| US-20240174636-A1 | NOVEL INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | IDO1, IDO2, INMT | ALDH1A1 1514/4885SGMS2 2117/4885KDM4E 120/4885 |
| US-20240239767-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | PCSK9, PCSK7, PCSK6 | ALDH1A1 4278/4885SGMS2 398/4885KDM4E 3214/4885 |
| US-20240409533-A1 | HMOX1 INDUCERS | HMOX1, HMOX2, HMBS | ALDH1A1 332/4885SGMS2 3766/4885KDM4E 2510/4885 |
| US-12071433-B2 | HMOX1 inducers | HMOX1, HMOX2, HMBS | ALDH1A1 223/4885SGMS2 3662/4885KDM4E 2606/4885 |
| US-20240051952-A1 | HMOX1 INDUCERS | HMOX1, HMOX2, QSOX1 | ALDH1A1 266/4885SGMS2 4349/4885KDM4E 4001/4885 |
| US-20190367499-A1 | Compounds for Pain Treatment, Compositions Comprising Same, and Methods of Using Same | OPRL1, OPRK1, OPRM1 | ALDH1A1 809/4885SGMS2 306/4885KDM4E 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.